Examination of the in vivo immune response elicited by Chlamydia psittaci in chickens.

It has since long been reported that Chlamydia psittaci is endemic in the poultry industry in Belgium as well as in other European Countries. This can lead to major economic losses because of a lowered egg production, higher mortality and carcass condemnation. Nowadays, expensive antibiotic treatments are necessary to reduce mortality rate but this can lead to antibiotic resistance.

Pathogenicity of low and highly virulent Chlamydia psittaci isolates for specific-pathogen-free chickens.

In commercially raised poultry, chlamydiosis mostly seems to occur on turkey or duck farms, sometimes associated with zoonotic transmission and disease (psittacosis) in humans. However, Chlamydia infections are apparently emerging in chickens, and information on the virulence of Chlamydia in chickens is limited. Up-to-date Chlamydia psittaci genotypes B and D are most frequently found in broilers.

Emerging Chlamydia psittaci infections in chickens and examination of transmission to humans.

Chlamydia psittaci and atypical Chlamydiaceae infections are (re)-emerging in chickens. We therefore examined the prevalence of C. psittaci, atypical Chlamydiaceae and their zoonotic transmission on 19 Belgian chicken farms.

Emerging Chlamydia psittaci infections in the chicken industry and pathology of Chlamydia psittaci genotype B and D strains in specific pathogen free chickens.

Sera of 30 Belgian and 10 Northern French chicken farms were tested by a Chlamydia (C.) psittaci major outer membrane protein (MOMP) based ELISA. Ninety-six percent, 93% and 90% of the Belgian broilers, broiler breeders and layers were seropositive.

Protection of pigs against genital Chlamydia trachomatis challenge by parenteral or mucosal DNA immunization.

The current study evaluates combined aerosol-vaginal delivery of a MOMP-based Chlamydia trachomatis (serovar E) DNA vaccine in a pig genital challenge model. Most non-replicating antigens are rather poor mucosal immunogens in comparison to replicating antigens. Therefore, a mucosal administered DNA vaccine, which actually mimics a live vaccine, could be promising.